Phase 2
N/A
N/A
Not Enrolling
Both
Calcinosis

Thank you

Trial Information


PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of salmon calcitonin
every 3 weeks. Ondansetron premedication and intravenous hydration are also administered.

Patients are followed for disease progression and tumor recurrence.

Inclusion Criteria


PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Histologically confirmed tumoral calcinosis --Prior/Concurrent
Therapy-- Prior surgical resection of calcinotic lesion required

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Principal Investigator

Craig B. Langman

Investigator Role:

Study Chair

Investigator Affiliation:

Ann & Robert H Lurie Children's Hospital of Chicago

Authority:

United States: Federal Government

Study ID:

199/11925

NCT ID:

NCT00004358

Start Date:

November 1992

Completion Date:

Related Keywords:

  • Calcinosis
  • arthritis & connective tissue diseases
  • rare disease
  • tumoral calcinosis
  • Calcinosis

Name

Location
Children's Memorial Hospital, Chicago Chicago, Illinois  60614